background
coronavirus
pose
seriou
threat
global
health
evidenc
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
sar
coronaviru
sarscov
mer
coronaviru
merscov
novel
coronaviru
previous
dub
offici
name
caus
agent
sar
mer
diseas
outbreak
respect
safe
vaccin
rapidli
induc
potent
longlast
virusspecif
immun
respons
infecti
agent
urgent
need
coronaviru
spike
protein
characterist
structur
compon
viral
envelop
consid
key
target
vaccin
prevent
coronaviru
infect
method
first
gener
codon
optim
subunit
vaccin
fuse
foldon
trimer
domain
mimic
nativ
viral
structur
variant
construct
engin
immun
stimul
flagellin
agonist
respect
trimer
design
comprehens
test
preclin
immunogen
merscov
vaccin
mice
deliv
subcutan
tradit
needl
inject
intracutan
dissolv
microneedl
array
mna
evalu
viru
specif
igg
antibodi
serum
vaccin
mice
elisa
use
viru
neutral
assay
driven
urgent
need
vaccin
util
strategi
rapidli
develop
mna
subunit
vaccin
test
preclin
immunogen
vivo
exploit
substanti
experi
mna
merscov
vaccin
find
describ
develop
mna
deliv
merscov
vaccin
preclin
immunogen
specif
mna
deliv
subunit
vaccin
elicit
strong
longlast
antigenspecif
antibodi
respons
build
ongo
effort
develop
merscov
vaccin
promis
immunogen
mnadeliv
merscov
vaccin
experi
mna
fabric
deliveri
includ
clinic
trial
rapidli
design
produc
clinicallytranslat
mna
subunit
vaccin
within
week
identif
sequenc
importantli
mna
deliv
subunit
vaccin
elicit
potent
antigenspecif
antibodi
respons
evid
begin
week
immun
interpret
mna
deliveri
subunit
vaccin
promis
immun
strategi
coronaviru
infect
progress
scientif
technolog
effort
enabl
quicker
respons
emerg
pandem
ongo
effort
develop
subunit
vaccin
enabl
us
rapidli
design
produc
mna
subunit
vaccin
capabl
induc
potent
virusspecif
antibodi
respons
collect
result
support
clinic
develop
mna
deliv
recombin
protein
subunit
vaccin
sar
mer
emerg
infecti
diseas
decemb
chines
author
wuhan
announc
cluster
pneumonia
case
unknown
etiolog
includ
patient
report
exposur
wuhan
huanan
seafood
wholesal
market
emerg
anoth
pathogen
zoonot
hcov
suspect
januari
chines
center
diseas
control
report
novel
coronaviru
caus
agent
shortli
thereaft
genom
sequenc
sever
isol
becam
publicli
avail
februari
name
diseas
caus
new
coronaviru
new
viru
name
sever
acut
respiratori
syndrom
coronaviru
genom
analys
indic
share
genom
similar
sarscov
within
receptorbind
motif
directli
contact
human
receptor
import
implic
vaccin
design
predict
pandem
potenti
humantohuman
transmiss
establish
situat
evolv
rapidli
number
verifi
case
grow
thousand
accordingli
world
health
organ
declar
global
pandem
anoth
recent
emerg
coronaviru
middl
east
respiratori
syndrom
coronaviru
merscov
first
isol
saudi
arabia
januari
world
health
organ
notifi
laboratoryconfirm
case
infect
merscov
includ
relat
death
fatal
rate
case
arisen
countri
global
includ
sever
outbreak
republ
korea
merscov
still
endem
middl
east
particularli
saudi
arabia
case
occur
efficaci
drug
vaccin
current
approv
human
use
includ
merscov
list
prioriti
blueprint
diseas
urgent
need
acceler
research
develop
safe
efficaci
vaccin
coronavirus
spike
protein
crucial
viral
transmiss
infect
determin
tropism
viru
host
cell
entri
bind
receptor
merss
bind
cellular
receptor
dipeptidyl
peptidas
via
receptorbind
domain
rbd
ntermin
surfac
subunit
employ
ctermin
transmembran
subunit
fuse
host
cell
membran
due
vital
function
properti
establish
antigen
protein
import
target
vaccin
develop
previou
studi
shown
adenovir
vaccin
candid
express
subunit
induc
efficaci
antibodymedi
neutral
activ
fulllength
suggest
subunit
immunogen
ideal
vaccin
candid
nativ
protein
exist
trimer
form
surfac
viru
howev
ectodomain
express
recombin
protein
eukaryot
system
protein
exist
predominantli
monomer
form
make
trimer
recombin
codon
optim
subunit
protein
mimick
nativ
viral
structur
fuse
segment
acid
sequenc
call
foldon
domain
natur
trimer
domain
deriv
c
terminu
bacteriophag
fibritin
inclus
foldon
trimer
domain
promot
trimer
structur
shown
increas
immunogen
sever
viral
antigen
includ
influenza
viru
hemagglutinin
glycoprotein
sarscov
support
import
mimick
nativ
viral
trimer
structur
recent
work
shown
recombin
trimer
receptorbind
domain
rbd
merscov
made
fuse
rbd
foldon
domain
rbdfd
elicit
potent
rbdspecif
neutral
antibodi
protect
transgen
mice
viral
infect
potenti
improv
immunogen
vaccin
also
construct
subunit
integr
tolllik
receptor
tlr
agonist
sequenc
specif
flagellin
c
synthet
form
lp
mimic
peptid
bind
induc
nuclear
local
transcript
factor
nfkb
result
transcript
inflammatori
cytokin
secret
chemokin
flagellin
highli
conserv
natur
bacteri
ligand
bind
activ
express
dendrit
cell
coronaviru
emerg
pathogen
exponenti
increas
signific
due
high
case
fatal
rate
larg
distribut
reservoir
lack
medic
countermeasur
public
health
emerg
caus
coronavirus
includ
sarscov
merscov
clearli
demonstr
urgenc
evalu
candid
vaccin
combat
outbreak
continu
research
effort
previou
epidem
contribut
effort
investig
quickli
develop
safe
vaccin
emerg
infect
howev
recent
pandem
highlight
import
continu
need
rapid
design
product
test
clinic
translat
candid
vaccin
studi
demonstr
rapid
develop
immunogen
novel
microneedl
array
mna
deliv
recombin
coronaviru
vaccin
mna
deliv
subunit
vaccin
induc
potent
longlast
antigen
antigenspecif
immun
respons
notabl
mna
deliveri
vaccin
gener
significantli
stronger
immun
respons
administ
tradit
subcutan
needl
inject
indic
improv
immunogen
skintarget
deliveri
effort
mna
subunit
vaccin
enabl
rapid
design
product
mna
vaccin
capabl
elicit
potent
virusspecif
antibodi
respons
evid
earli
week
immun
rapid
design
product
mnaembed
subunit
vaccin
use
clinic
applic
mna
fabric
method
support
develop
mna
deliv
recombin
coronaviru
vaccin
clinic
vaccin
applic
collect
studi
support
clinic
develop
mna
protein
subunit
vaccin
emerg
infecti
diseas
mna
deliveri
subunit
vaccin
promis
immun
strategi
merscov
infect
adapt
subunit
vaccin
broad
rang
infecti
diseas
recent
advanc
recombin
dna
technolog
vaccin
deliveri
strategi
enabl
quick
design
product
test
vaccin
emerg
infect
plan
evalu
vaccin
import
predictor
vaccin
efficaci
human
includ
induct
neutral
antibodi
abil
prevent
infect
anim
challeng
model
assay
preclin
model
becom
avail
thu
far
studi
suggest
may
possibl
produc
clinic
grade
vaccin
novel
pathogen
human
test
subsequ
global
distribut
time
significantli
impact
spread
diseas
neutrophil
lung
epitheli
cell
pneumonocyt
augment
immunogen
sever
vaccin
model
skin
ideal
target
immun
contain
rich
popul
antigen
present
immun
accessori
cell
capabl
induc
proinflammatori
microenviron
favor
induct
potent
durabl
adapt
immun
sever
emerg
skintarget
drug
deliveri
method
dissolv
mna
emerg
minimallyinvas
intracutan
approach
mna
use
develop
mechan
strong
watersolubl
polym
physic
breach
outermost
layer
skin
stratum
corneum
rapidli
dissolv
underli
viabl
epidermi
dermi
deliv
cargo
skin
microenviron
importantli
mna
deliveri
result
high
concentr
vaccin
compon
local
skin
microenviron
therebi
contribut
dosespar
effect
could
decreas
requir
vaccin
dose
efficaci
immun
substanti
reduc
cost
toxic
although
stabil
vaccin
candid
mna
need
valid
differ
temperatur
vari
storag
period
avail
literatur
indic
mnaembed
vaccin
potenti
remain
stabl
extend
period
time
without
expens
cold
chain
requir
previou
anim
clinic
studi
suggest
mna
could
provid
safe
welltoler
deliveri
platform
efficaci
immun
strategi
demonstr
rapid
develop
mna
subunit
vaccin
promis
immunogen
mice
develop
use
evolv
experi
merscov
vaccin
mna
first
evalu
immunogen
trimer
form
subunit
vaccin
deliv
subcutan
tradit
needl
inject
intracutan
mna
driven
promis
immunogen
vaccin
urgent
need
respond
recent
coronaviru
pandem
rapidli
within
week
identif
sequenc
design
produc
mna
vaccin
test
immunogen
mice
describ
rapid
develop
mna
embed
subunit
vaccin
use
clinicallyapplic
mna
product
method
reli
experi
clinic
trial
util
mna
deliveri
clinicaltrialsgov
identifi
taken
togeth
result
support
develop
mna
deliv
recombin
coronaviru
vaccin
clinic
applic
codonoptim
gene
encod
amino
acid
fulllength
mer
accord
genebank
lack
stop
codon
flank
sali
bamhi
amplifi
pcr
use
replac
zikv
pad
zikvefl
sali
bamhi
site
fuse
bamh
ilink
fibritin
foldon
trimer
domain
f
tobacco
etch
viru
proteas
tp
six
histidin
tag
gener
plasmid
construct
bamh
replac
codon
optim
bamh
apphal
bamh
ifflic
genbank
subsequ
replicationdefect
human
adenoviru
serotyp
design
made
loxp
homolog
recombin
purifi
store
describ
previous
construct
codonoptim
gene
encod
amino
acid
fulllength
gisaid
access
id
lack
stop
codon
flank
hindiiisali
synthes
genscript
gener
subclon
codonoptim
gene
pmaxclon
lonza
hindiiinoti
site
construct
bamh
replac
codon
optim
bamh
apphal
recombin
protein
name
express
human
embryon
kidney
hek
cell
infect
respect
purifi
ni
superflow
resin
clontech
nativ
condit
supernat
describ
previous
briefli
purifi
recombin
protein
treat
actev
proteas
life
technolog
follow
affin
chromatographi
ni
superflow
resin
remov
sixhistidin
tag
polyhistidin
tag
proteas
cleavag
reaction
cleav
nativ
recombin
protein
collect
flowthrough
fraction
elut
solut
concentr
desalt
phosphat
buffer
salin
pb
amicon
ultra
centrifug
filter
devic
millipor
express
recombin
protein
cell
transfect
electropor
celetrix
briefli
cell
count
suspend
plasmid
electropor
buffer
cell
mixtur
contain
cell
plasmid
transfer
celetrix
electropor
tube
mm
distanc
electrod
immedi
subject
electropor
incub
hr
humidifi
atmospher
co
recombin
protein
purifi
ni
superflow
resin
clontech
nativ
condit
supernat
describ
previous
concentr
purifi
recombin
protein
determin
bradford
assay
use
bovin
serum
albumin
bsa
protein
standard
evalu
recombin
adenovirus
cell
transduc
ten
multipl
infect
moi
six
hour
infect
cell
wash
three
time
pb
ad
serumfre
media
incub
h
supernat
infect
adenovirus
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
western
blot
briefli
supernat
boil
laemmli
sampl
buffer
contain
sd
nativ
sampl
buffer
without
betamercaptoethanol
bme
protein
separ
trisglycin
sdspage
gel
transfer
polyvinyliden
fluorid
pvdf
membran
block
room
temperatur
nonfat
milk
pbst
monoclon
antibodi
invitrogen
ad
incub
overnight
primari
antibodi
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
santacruz
ad
incub
rt
h
secondari
antibodi
wash
three
time
pb
signal
visual
use
ecl
western
blot
substrat
reagent
amersham
hyperfilm
ge
healthcar
dissolv
microneedl
array
mna
incorpor
protein
fabric
carboxymethyl
cellulos
cmc
kda
mw
room
temperatur
use
previous
describ
threestag
mna
manufactur
strategi
briefli
product
mold
prepar
cast
polydimethylsiloxan
pdm
sylgard
elastom
onto
micromachin
mna
master
mold
includ
obeliskshap
microneedl
array
height
width
apex
angl
microneedl
chosen
mm
mm
respect
next
cmcbase
vaccin
produc
twostep
spindri
techniqu
first
ml
purifi
protein
dispens
onto
mna
product
mold
centrifug
min
g
fill
microneedl
caviti
subsequ
excess
solut
remov
residu
protein
solut
spindri
tip
microneedl
caviti
mold
centrifug
g
min
tipload
protein
product
mold
overlay
mg
cmc
hydrogel
ww
form
mechan
strong
microneedl
back
layer
mna
mold
load
cmchydrogel
centrifug
h
g
obtain
final
dissolv
mna
vaccin
theoret
load
mg
mg
mg
mg
mg
protein
respect
geometr
integr
fabric
mna
confirm
optic
stereomicroscopi
imag
experi
importantli
mna
design
fabric
strategi
also
use
mna
util
ongo
phase
clinic
trial
clinicaltrialsgov
identifi
line
effort
toward
clinic
product
mna
subunit
vaccin
gamma
irradi
kgi
steril
small
group
mna
subunit
vaccin
determin
clinic
relev
steril
condit
effect
immunogen
bablc
mice
five
anim
per
group
inocul
subcutan
mg
mg
plu
mg
mpla
monophosphoryl
lipid
agonist
mg
mg
pb
neg
control
vp
posit
control
note
mpla
ad
singl
control
group
similar
dose
use
previous
establish
posit
control
adjuv
subunit
vaccin
mna
vaccin
appli
abdomen
anesthet
mice
remov
min
two
week
primari
immun
mice
boost
intranas
intracutan
mna
dose
correspond
immunogen
studi
femal
mice
five
anim
per
group
inocul
intracutan
mna
load
protein
pb
neg
control
two
week
primari
immun
mice
similarli
boost
dose
correspond
immunogen
preliminarili
evalu
effect
steril
gamma
irradi
vaccin
mice
per
group
irradi
use
clinic
steril
condit
mice
bled
saphen
vein
week
serum
sampl
evalu
antibodi
enzymelink
immunosorb
assay
elisa
mice
maintain
specif
pathogenfre
condit
univers
pittsburgh
experi
mice
conduct
accord
anim
use
guidelin
protocol
approv
univers
pittsburgh
institut
anim
care
use
iacuc
committe
two
week
prime
immun
pool
sera
obtain
mice
screen
merssspecif
antibodi
use
fluorescenceactiv
cell
sorter
fac
analysi
human
embryon
kidney
hek
cell
transfect
either
padmerss
pad
control
use
lipofectamin
invitrogen
describ
previous
briefli
h
transfect
cell
harvest
trypsin
incub
trypsin
edta
min
follow
trypsin
inactiv
ad
volum
fb
media
wash
phosphat
buffer
salin
pb
incub
mous
antiserum
group
follow
stain
peconjug
antimous
secondari
igg
antibodi
jackson
immuno
research
data
acquisit
analysi
perform
use
lsrii
bd
flowjo
tree
star
softwar
sera
anim
collect
everi
two
week
test
proteinspecif
igg
convent
elisa
previous
describ
longlast
immun
sera
anim
collect
week
week
primari
inocul
test
proteinspecif
igg
elisa
briefli
plate
coat
serumfre
media
cell
infect
moi
h
overnight
carbon
buffer
ph
block
pb
contain
tween
pbst
bovin
serum
albumin
bsa
hr
mous
sera
dilut
pbst
bsa
incub
two
hour
plate
wash
antimous
igghorseradish
peroxidas
hrp
santacruz
ad
well
incub
one
hour
plate
wash
three
time
develop
reaction
stop
h
absorb
nm
determin
use
elisa
reader
perkinelm
bind
recombin
protein
mous
sera
plate
coat
ng
purifi
recombin
protein
per
well
overnight
carbon
coat
buffer
ph
follow
addit
dilut
preimmun
sera
sera
mous
infect
carri
sequenti
base
protocol
similar
describ
elisa
antibodi
plate
coat
ng
purifi
per
well
overnight
carbon
coat
buffer
ph
follow
addit
dilut
mous
sera
carri
sequenti
base
protocol
similar
describ
test
merscov
neutral
activ
sera
deriv
mice
immun
mpla
pb
previous
describ
mous
sera
obtain
retroorbit
plexu
everi
two
week
six
week
test
abil
neutral
merscov
emc
isol
briefli
viru
pfu
premix
serial
dilut
sera
anim
group
prior
inocul
onto
vero
cell
viral
infect
monitor
occurr
cytopath
effect
h
postinfect
viru
neutral
titer
vnt
determin
highest
serum
dilut
show
full
protect
cytopath
effect
merscov
statist
analys
perform
use
graphpad
prism
san
diego
ca
data
analyz
oneway
anova
follow
tukey
posthoc
test
differ
consid
signific
p
construct
recombin
trimer
protein
codonoptim
fuse
fibritin
foldon
trimer
domain
two
addit
variant
engin
integr
agonist
peptid
salmonella
typhimurium
flagellin
c
flic
fragment
ctermin
foldon
moreov
three
antigen
design
tag
tobacco
etch
viru
tev
proteas
cleavag
sequenc
carboxi
terminu
allow
metal
chelat
affin
purif
facilit
downstream
largescal
purif
compat
clinic
manufactur
fig
shuttl
vector
gener
replicationdefect
adenoviru
design
produc
loxp
homolog
recombin
use
posit
control
determin
whether
would
form
trimer
structur
serumfre
supernat
cell
infect
adenoviru
character
sdspage
western
blot
analysi
three
recombin
protein
design
tag
carboxytermin
end
recogn
monoclon
antibodi
expect
glycosyl
monom
molecular
weight
kda
kda
kda
denatur
reduc
bme
condit
higher
molecularweight
band
dimer
trimer
evid
denatur
nonreduc
without
bme
condit
time
reduc
protein
monom
expect
fig
boil
sampl
buffer
protein
still
migrat
posit
trimer
indic
remark
stabil
protein
result
demonstr
recombin
form
trimer
conform
presenc
fd
trimer
motif
addit
delet
sixhistidin
tag
purifi
recombin
protein
treat
actev
proteas
life
technolog
follow
affin
chromatographi
nickel
chelat
resin
remov
sixhistidin
tag
polyhistidin
tag
proteas
cleavag
reaction
cleav
nativ
recombin
protein
collect
flowthrough
fraction
use
coat
antigen
follow
detect
mous
serum
three
purifi
recombin
protein
detect
use
serum
mice
immun
p
oneway
anova
follow
tukey
posthoc
test
prepar
laboratori
previous
specif
antibodi
bind
activ
detect
serum
preimmun
mice
control
mice
inocul
fig
elisa
data
reveal
three
recombin
protein
strong
reactiv
antibodi
next
determin
whether
recombin
subunit
vaccin
could
elicit
antigenspecif
immun
respons
vivo
balbc
mice
inocul
subcutan
mg
mg
mg
mg
plu
mg
mpla
adjuv
deliv
molar
ratio
immunogen
pb
neg
control
day
experiment
schedul
shown
fig
two
week
immun
obtain
sera
examin
bind
membranebound
merss
measur
reactiv
cell
transfect
padmerss
pad
use
flow
cytometri
shown
fig
presenc
mpla
adjuv
induc
strong
membranebound
merssspecif
igg
antibodi
respons
p
oneway
anova
follow
tukey
posthoc
test
signific
antibodi
respons
detect
mous
sera
compar
pbsimmun
mous
sera
hand
absenc
adjuv
sequenc
mna
intracutan
deliveri
molar
ratio
elicit
potent
igg
antibodi
respons
p
oneway
anova
follow
tukey
posthoc
test
significantli
stronger
seen
sc
immun
mice
mpla
adjuv
p
oneway
anova
follow
tukey
posthoc
test
indic
potenti
mna
effect
recombin
coronaviru
vaccin
deliveri
platform
fig
mice
immun
posit
control
develop
significantli
higher
level
igg
antibodi
cell
membranebound
merss
compar
neglig
igg
level
control
mice
inocul
pb
antibodi
detect
bound
cell
transfect
pad
without
immunogen
insert
data
shown
data
indic
protein
mpla
adjuv
mna
deliv
induc
strong
antibodi
respons
membranebound
merss
two
week
singl
immun
investig
immunogen
trimer
protein
two
four
week
boost
immun
sera
obtain
mice
screen
specif
antibodi
elisa
shown
fig
follow
sc
vaccin
elicit
igg
antibodi
respons
p
oneway
anova
follow
tukey
posthoc
test
week
antibodi
respons
detect
mous
sera
vaccin
mice
compar
pbsimmun
mous
sera
howev
week
boost
antigenspecif
igg
detect
sera
sc
immun
mice
although
antibodi
titer
gener
low
except
sc
deliv
induc
rel
strong
igg
antibodi
respons
p
oneway
anova
follow
tukey
posthoc
test
week
importantli
mice
immun
vaccin
variant
mna
deliveri
demonstr
significantli
higher
level
antigenspecif
igg
p
oneway
anova
follow
tukey
posthoc
test
compar
mice
immun
pb
signific
differ
mna
vaccin
variant
fig
demonstr
immunogen
merscov
subunit
vaccin
mous
sera
also
test
abil
neutral
merscov
emc
isol
shown
fig
detect
merscovneutr
antibodi
sera
mice
immun
sc
week
howev
week
sera
anim
immun
mpla
signific
compar
level
viru
neutral
activ
geometr
mean
neutral
titer
respect
titer
fold
higher
sera
mice
immun
vnt
mean
importantli
shown
fig
week
group
mna
immun
mice
develop
signific
level
neutral
antibodi
p
oneway
anova
follow
tukey
posthoc
test
anim
immun
geometr
mean
neutral
titer
respect
expect
neutral
activ
detect
sera
mice
immun
pb
result
suggest
mna
deliveri
candid
subunit
vaccin
gener
strong
antibodymedi
neutral
activ
approach
induc
live
adenovector
immun
exce
observ
sc
deliveri
even
potent
exogen
adjuv
ad
sc
vaccin
promis
immunogen
mna
merscov
vaccin
without
chemic
adjuv
make
ideal
candid
futur
clinic
studi
evalu
persist
immun
mous
sera
collect
week
immun
evalu
presenc
igg
elisa
anim
group
immun
sc
recombin
subunit
vaccin
demonstr
level
igg
specif
antibodi
later
time
point
observ
week
surprisingli
mice
immun
sc
significantli
higher
level
igg
p
oneway
anova
follow
tukey
posthoc
test
week
compar
observ
week
fig
sustain
week
importantli
mna
deliv
antibodi
supernat
resolv
polyacrylamid
gel
boil
sd
sampl
buffer
without
bme
c
detect
purifi
mous
sera
recombin
protein
purifi
use
ni
superflow
resin
nativ
condit
cleavag
fusion
protein
tev
proteas
tag
proteas
remov
cleavag
reaction
affin
chromatographi
nickel
chelat
resin
three
coat
plate
elisa
detect
mous
sera
signific
determin
oneway
anova
follow
tukey
test
p
vaccin
demonstr
gener
increas
statist
signific
level
antibodi
time
point
fig
signific
differ
observ
mice
immun
pb
time
point
evalu
result
indic
mnadeliv
subunit
vaccin
induc
potent
longlast
specif
antibodi
respons
mna
deliveri
viabl
approach
clinic
develop
subunit
vaccin
emerg
infecti
diseas
base
vaccin
result
urgenc
public
health
threat
focus
effort
develop
subunit
vaccin
shown
fig
size
trimer
product
vaccin
confirm
western
blot
fig
aggreg
fig
could
attribut
trimer
segment
ntd
domain
abil
histidin
tag
oligomer
tag
protein
use
mna
vaccin
mice
subunit
vaccin
sera
collect
prior
immun
week
week
evalu
presenc
specif
antibodi
elisa
previous
describ
shown
fig
significantli
high
p
oneway
anova
follow
tukey
posthoc
test
igg
respons
detect
earli
week
subunit
vaccin
compar
control
group
inclus
ligand
trimer
subunit
result
neglig
effect
specif
igg
titer
preliminari
studi
immunogen
gamma
irradi
steril
mna
vaccin
compar
unirradi
mna
vaccin
data
shown
therebi
support
feasibl
gamma
irradi
termin
steril
approach
clinic
subunit
vaccin
reli
experi
merscov
sarscov
vaccin
experi
clinic
product
human
applic
mna
develop
standard
oper
procedur
sop
rapid
develop
clinic
grade
mna
subunit
vaccin
product
strategi
relat
timelin
outlin
tabl
first
design
optim
clone
subunit
begin
sequenc
becam
publicli
avail
subsequ
produc
subunit
protein
purifi
h
posttransfect
bind
merss
cell
surfac
analyz
incub
mice
sera
obtain
week
immun
follow
stain
peconjug
antimous
igg
st
signific
determin
oneway
anova
follow
tukey
test
p
fig
induct
humor
immun
respons
mice
vaccin
recombin
vaccin
balbc
mice
immun
subcutan
intracutan
mg
subunit
vaccin
sc
without
mg
mpla
mna
deliveri
subunit
protein
vp
posit
control
day
mice
boost
use
regimen
prime
immun
week
treatment
immun
sera
mice
collect
dilut
test
presenc
antibodi
elisa
b
merscovneutr
assay
without
dilut
c
merscov
virusneutr
titer
vnt
measur
everi
week
primari
immun
use
vero
cell
determin
highest
dilut
inhibit
merscov
infect
signific
determin
oneway
anova
follow
tukey
test
p
black
circl
fig
repres
week
week
respect
fig
longev
immun
respons
mice
vaccin
subunit
vaccin
balbc
mice
immun
subunit
vaccin
describ
fig
legend
week
immun
sera
collect
dilut
pb
test
presenc
antibodi
elisa
signific
determin
oneway
anova
follow
tukey
test
p
monoclon
antibodi
purifi
protein
resolv
trisglycin
gel
boil
sd
sampl
buffer
bme
nativ
sampl
buffer
without
bme
c
mice
immun
intraderm
mna
contain
mg
immun
sera
mice
collect
everi
week
dilut
pb
test
presenc
antibodi
elisa
signific
determin
oneway
anova
follow
tukey
test
p
subunit
protein
product
purif
valid
incorpor
subunit
dissolv
mna
syring
use
process
develop
clinic
product
qualiti
control
mna
clinicaltrialsgov
identifi
follow
gamma
irradi
assur
steril
vaccin
load
mna
syring
use
control
group
clinic
trial
analysi
establish
releas
criteria
latter
ongo
use
applic
ind
approv
enabl
safeti
focus
phase
clinic
trial
present
rapid
design
translat
develop
mna
vaccin
capabl
gener
potent
antigenspecif
antibodi
respons
capit
substanti
experi
coronaviru
vaccin
mna
deliveri
platform
first
describ
design
product
trimer
recombin
subunit
vaccin
without
integr
immunostimulatori
tlr
ligand
sequenc
test
immunogen
vaccin
variant
deliv
either
tradit
subcutan
needl
inject
use
mna
specif
target
vaccin
compon
immun
fertil
skin
microenviron
found
mna
deliveri
vaccin
induc
stronger
humor
respons
tradit
needl
inject
regardless
inclus
tlr
ligand
bind
sequenc
fig
b
hand
integr
bind
sequenc
subunit
trimer
result
rel
stronger
antibodi
respons
without
vaccin
deliv
subcutan
inject
fig
interestingli
inclus
flagellin
bind
sequenc
effect
immunogen
sc
deliv
vaccin
fig
importantli
signific
neutral
activ
observ
vaccin
anim
week
consist
previou
igg
result
presenc
subunit
trimer
improv
neutral
function
antibodi
sc
immun
mice
immunogen
result
signific
neutral
notabl
mna
deliveri
effect
elicit
neutral
antibodi
vaccin
mna
vaccin
gener
higher
level
neutral
antibodi
even
beyond
induc
sc
deliv
mpla
adjuv
vaccin
similar
seen
follow
deliveri
construct
via
recombin
adenovir
vector
though
level
neutral
antibodi
elev
mice
immun
trimer
includ
either
flagellin
increas
statist
signific
compar
mna
vaccin
alon
fig
thu
though
contribut
integr
tlr
ligand
strong
immun
respons
induc
mna
vaccin
appear
minim
provid
promis
benefit
sc
vaccin
administr
potenti
contribut
immunogen
human
yet
determin
importantli
other
shown
effect
protect
merscov
challeng
mice
compar
lower
neutral
titer
previou
passiv
immunotherapi
studi
merscovspecif
antibodi
neutral
sera
obtain
merscov
immun
human
anim
furthermor
previous
demonstr
antibodi
direct
domain
spike
protein
detect
studi
elisa
exert
neutral
activ
live
coronavirus
base
result
vaccin
focus
effort
develop
mna
vaccin
use
describ
approach
within
three
week
public
glycoprotein
sequenc
produc
immunogen
fabric
dissolv
mna
incorpor
vaccin
quantiti
suffici
preclin
test
mna
deliveri
either
induc
substanti
statist
signific
increas
antigenspecif
antibodi
respons
soon
week
compar
preimmun
week
respons
inclus
signific
effect
antibodi
titer
time
point
furthermor
immunogen
mna
vaccin
maintain
gamma
irradi
steril
suggest
viabl
method
assur
steril
mna
vaccin
clinic
applic
signific
antibodi
titer
observ
earli
time
point
boost
strongli
support
feasibl
vaccin
particularli
context
similar
result
obtain
analog
construct
condit
neutral
assay
import
ensur
antibodi
function
howev
earli
timepoint
access
valid
assay
neutral
antibodi
time
submiss
manuscript
four
week
postimmun
base
merscov
studi
reliabl
detect
neutral
antibodi
may
requir
least
six
week
post
immun
specul
delay
neutral
respons
like
result
time
need
affin
matur
neutral
igg
antibodi
howev
believ
vaccin
like
induc
neutral
immun
suggest
vigor
earli
antibodi
respons
common
vaccin
virus
accordingli
even
though
still
earli
predict
whether
human
immun
vaccin
candid
similar
respons
protect
merscov
infect
studi
demonstr
develop
product
initi
anim
test
clinic
translat
mna
vaccin
candid
emerg
infect
rapidli
accomplish
studi
directli
assess
import
correl
human
efficaci
would
provid
addit
support
efficaci
human
regard
import
determin
whether
antibodi
immun
anim
neutral
viru
infect
demonstr
protect
infect
anim
challeng
model
transgen
mous
model
would
inform
plan
studi
model
develop
valid
final
note
immunogen
differ
mna
coronaviru
vaccin
coronaviru
vaccin
deliv
tradit
needl
inject
observ
need
evalu
clinic
trial
establish
clinic
advantag
mna
deliveri
microneedl
array
mediat
immun
sever
mechanist
differ
tradit
intramuscular
subcutan
needl
inject
could
explain
variat
magnitud
kinet
ensu
respons
skin
immunolog
reactiv
contain
high
densiti
antigen
present
immuneaccessori
cell
innat
immun
function
includ
keratinocyt
mast
cell
innat
lymphocyt
redund
skin
immunoregulatori
circuit
respond
wide
varieti
damag
infect
relat
signal
rapidli
orchestr
innat
immun
respons
mna
deliv
vaccin
compon
defin
space
within
skin
microenviron
result
high
vaccin
concentr
rel
low
dose
antigen
deliveri
mna
deliveri
antigen
target
skin
microenviron
result
prolong
exposur
skin
resid
antigen
present
cell
innat
immun
cell
skin
deliv
compon
moreov
transient
mechan
stress
microneedl
insert
induc
natur
local
innat
immun
respons
serv
physic
adjuv
enhanc
antigenspecif
adapt
immun
mna
deliveri
lower
dose
local
space
improv
safeti
reduc
system
exposur
mna
deliveri
potenti
acceler
process
vaccin
product
significantli
reduc
cost
consider
reduc
requir
vaccin
dose
stabil
studi
mna
vaccin
current
progress
howev
evid
literatur
vaccin
compon
includ
protein
typic
stabil
integr
mna
polym
matrix
retain
conform
structur
evidenc
mainten
antibodi
bind
function
retain
immunogen
recombin
adenoviru
vaccin
least
month
thu
mna
vaccin
offer
potenti
elimin
substanti
cost
associ
cold
chain
necessari
current
vaccin
final
mna
describ
design
appli
without
need
applic
special
equip
support
potenti
selfadministr
featur
provid
sever
import
advantag
support
futur
develop
mna
vaccin
global
protect
rapidli
emerg
infecti
diseas
taken
togeth
studi
demonstr
speed
vaccin
emerg
infect
design
produc
use
recent
advanc
recombin
dna
technolog
combin
emerg
biotechnolog
method
bioengin
advanc
vaccin
deliveri
strategi
may
possibl
rapidli
produc
clinicallytranslat
vaccin
novel
pathogen
human
test
subsequ
global
distribut
time
significantli
impact
spread
diseas
